Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1341087 | 1.00 | MAPT (0.38) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL426250 | 0.94 | MEN1 (0.37) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL4410135 | 0.94 | MEN1 (0.37) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL6112028 | 0.94 | MEN1 (0.37) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL167196 | 0.91 | MEN1 (0.38) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL18104058 | 0.91 | MEN1 (0.40) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL167529 | 0.88 | MEN1 (0.38) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL9025723 | 0.88 | MEN1 (0.39) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL3295013 | 0.88 | MEN1 (0.39) | MAPTMEN1KMT2AATML3MBTL1 | |
| Acetic Acid SCHEMBL4704955 | 0.88 | MAPT (0.40) | MAPTMEN1KMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024147287-A1 | ACTIVE LIGHT SENSITIVE OR RADIATION SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD FOR PRODUCING ELECTRONIC DEVICE | 富士フイルム株式会社 | 2024-07-11 | — | — | WO | disclosed |
| CN-110475785-B | Peptide compound, method for producing same, composition for screening, and method for selecting peptide compound | 富士胶片株式会社 | 2023-06-13 | — | — | CN | disclosed |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | FUJIFILM CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| US-20200040039-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORPORATION (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-3604326-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| CN-110475785-A | The selection method of peptide compounds and its manufacturing method, screening composition and peptide compounds | FUJIFILM CORP | 2019-11-19 | — | — | CN | disclosed |
| EP-2098513-B1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8895551-B2 | Acrylamide compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| EP-2141150-B1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8247429-B2 | Tricyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| CN-101193873-A | Method for the production of substituted azoles | LANXESS DEUTSCHLAND GMBH (DE) | 2008-06-04 | — | — | CN | disclosed |
| US-20060004107-A1 | Method for designing a pharmaceutical compound specific to a desired receptor, a designed compound thereby, and pharmaceutical compositions containing the same | OJIMA MASANORI | 2006-01-05 | — | — | US | disclosed |
| EP-1046635-B1 | Process for preparing an aromatic compound substituted by a tertiary nitrile | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | disclosed |
| CN-1138756-C | Preparation of tirt nitrile substituted aromatic compound | �Ʒ� | 2004-02-18 | — | — | CN | disclosed |
| US-6303782-B1 | TREATING A FLUORINE-SUBSTITUTED AROMATIC COMPOUND WITH A SECONDARY NITRILE IN THE PRESENCE OF A BASE | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| EP-0769011-B1 | HERBICIDAL 1,2,4,6-THIATRIAZINES | SYNGENTA PARTICIPATIONS AG (CH) | 2001-08-29 | — | — | EP | disclosed |
| CN-1271723-A | Preparation of tirt nitrile substituted aromatic compound | PFIZER PRODUCT CO (US) | 2000-11-01 | — | — | CN | disclosed |
| EP-1046635-A1 | Process for preparing an aromatic compound substituted by a tertiary nitrile | Pfizer Products Inc. (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-0769011-A1 | HERBICIDAL 1,2,4,6-THIATRIAZINES | Novartis AG (CH) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001814-A1 | HERBICIDAL 1,2,4,6-THIATRIAZINES | CIBA-GEIGY AG (CH) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040039-A1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | VIP, NPPA, NGLY1 | MAPT 3979/4885MEN1 329/4885KMT2A 4395/4885 |
| US-20060004107-A1 | Method for designing a pharmaceutical compound specific to a desired receptor, a designed compound thereby, and pharmaceutical compositions containing the same | TBXA2R, PTAFR, PTGIR | MAPT 4321/4885MEN1 3230/4885KMT2A 4694/4885 |
| US-11319347-B2 | Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound | VIP, NPPA, NGLY1 | MAPT 3979/4885MEN1 329/4885KMT2A 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.